Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C

Table 1 Patient characteristics

Pt. No.	Age (yr)	Gender	Genotype	Viral load (IU/mL)	ALT (IU/L)	Hb (g/dL)	Neutrophil (/mm3)	PLT (× 103/mm3)	Naive/ re-treatment
1	51	M	2a	2.4 × 104	83	10.5	2729	254	Naive
2	56	M	1b	7.6 × 103	14	14.0	2565	268	Naive
3	26	F	2a	2.7 × 104	157	15.6	5217	284	Naive
4	67	M	2a	< 5.0 × 103	63	15.2	3940	159	Naive
5	48	F	2a	1.1 × 104	121	12.1	1851	146	Naive
6	48	F	2a	7.0 × 104	48	12.7	3084	244	Naive
7	70	M	2a	5.3 × 104	119	13.7	2002	157	Naive
8	64	M	ND	< 5.0 × 103	65	14.5	2200	148	Naive
9	22	M	ND	< 5.0 × 103	51	15.3	5003	308	Naive
10	40	F	2a	1.1 × 104	198	14.2	2424	190	Naive
11	68	F	2a	9.3 × 103	31	11.8	3567	212	Naive
12	60	M	2a	< 5.0 × 103	18	14.9	1520	265	Naive
13	68	F	2a	1.8 × 104	112	13.4	3338	190	Naive
14	76	M	2a	1.8 × 104	39	13.6	2540	272	Naive
15	25	F	2a	8.6 × 104	181	12.2	2649	260	Naive
16	28	F	2b	1.9 × 104	19	14.4	3522	324	Re-treatment
17	23	M	ND	< 5.0 × 103	456	15.0	3483	257	Naive
18	57	F	2b	5.9 × 103	97	14.2	2080	306	Naive
19	48	M	2a	6.4 × 104	41	15.1	1688	235	Naive
20	56	M	2b	5.1 × 104	124	15.1	3810	82	Naive
21	34	F	2a	2.8 × 104	72	13.4	4004	98	Naive
22	32	F	2a	1.7 × 104	41	12.5	1853	259	Naive
23	74	M	ND	< 5.0 × 103	37	10.6	1784	92	Naive
24	45	M	2a	1.0 × 104	41	16.3	4606	147	Naive
25	76	F	2a	< 5.0 × 103	54	10.9	2948	192	Naive
26	53	F	1b	5.0 × 103	13	11.9	3438	204	Naive
27	27	F	ND	< 5.0 × 103	46	15.1	2205	169	Naive
28	71	F	ND	5.0 × 103	40	14.1	2022	98	Naive
29	70	M	2a	5.1 × 104	81	14.5	2894	125	Naive
30	60	M	1b	5.7 × 103	40	15.1	1502	297	Naive
31	57	M	2a	2.8 × 104	61	15.5	3154	137	Naive
32	77	M	2a	< 5.0 × 103	68	10.3	1430	125	Naive
33	69	F	1b	1.6 × 104	21	12.8	2772	186	Naive
34	37	F	2a	< 5.0 × 103	42	13.1	2343	314	Naive
35	23	M	ND	< 5.0 × 103	46	14.6	2772	238	Naive
36	36	M	2a	1.3 × 104	26	14.5	5126	242	Naive
37	57	F	2b	4.7 × 104	50	14.9	1628	130	Naive
38	71	M	2a	3.5 × 104	102	14.4	3852	109	Naive
mean ± SD	52.0 ± 17.8				76.8 ± 77.6	13.7 ± 1.5	2838.20 ± 972.50	212.9 ± 79.1

ND: Not determined; ALT: Alanine transaminase; Hb: Hemoglobin; PLT: Platelet.

Table 2 Adverse events

Adverse event	n (%)
Flu-like symptoms
Fever	20 (52.6)
Pain	12 (31.5)
Fatigue	13 (34.2)
Insomnia	7 (18.4)
Neutropenia (< 750/mm3)	3 (7.9)
Skin symptoms	3 (7.9)
Emotional lability	3 (7.9)
Gastrointestinal symptoms	2 (3.3)
Thrombocytopenia (< 50 000/mm3)	1 (2.6)
Bacterial pneumonia	1 (2.6)
Influenza viral infection	1 (2.6)
Vertigo	1 (2.6)
Stomatitis	1 (2.6)